Can a fast-acting psychedelic drug ease depression?
Yes. In this trial, a single dose of the short-acting psychedelic DMT lowered depression scores far more than a placebo, and the benefit lasted up to three months. Two weeks after one infusion, the DMT group improved by about 7 more points on a standard depression scale than the placebo group.
Major depression is one of the leading causes of disability in the world. Standard antidepressants help many people, but not everyone. A large share of patients get little relief or cannot tolerate the side effects. That gap has pushed researchers to test new options, including psychedelic drugs. This new phase IIa trial looked at DMT, a serotonergic psychedelic that works fast and clears the body quickly.
How the treatment works
DMT is a natural compound that acts mainly on a brain receptor called the serotonin 5-HT2A receptor. This receptor helps control mood, thinking, and how we take in the world around us. Classic psychedelics like psilocybin act on the same target and have shown strong antidepressant effects in earlier studies.
What makes DMT stand out is speed. When given through a vein, it has a half-life of about five minutes. The psychedelic experience is short, so a therapy session can be much briefer than one built around psilocybin or LSD. That could make treatment easier to schedule and cheaper to run in a clinic.
What the data show
The trial enrolled 34 adults with moderate-to-severe depression. Researchers randomly split them into two groups of 17. One group got a single 21.5 mg dose of DMT infused over 10 minutes. The other got a placebo. Both groups also received supportive therapy from trained staff. Neither the patients nor the staff knew who got the real drug, which is the gold standard for a fair test.
Two weeks after dosing, the DMT group showed a much bigger drop in depression scores on the Montgomery-Asberg Depression Rating Scale, a common tool doctors use to measure mood. The difference was 7.35 points in favor of DMT, and the result was statistically meaningful (P = 0.023). The effect size was 0.82, which counts as large in this kind of research. About 35 percent of DMT patients responded, meaning their scores fell by at least half, compared with 12 percent on placebo.
Dr. Kumar’s Take
I find this really promising, but I want to be clear about what it is and is not. This is an early phase IIa trial with only 34 people, so the numbers can shift a lot in larger studies. What excites me is the practicality. A five-minute half-life means the intense part of the experience is over quickly, which could cut the time and staffing that psychedelic therapy usually demands. That matters if we ever want treatments like this to reach real clinics and not just research centers. Still, DMT was given with psychological support in a controlled setting, and that support is likely part of why it worked. This is not a drug to try on your own.
Who this might help
The study focused on people with moderate-to-severe depression, the group that often struggles most with standard care. In an open-label phase, everyone was offered a second DMT dose. The antidepressant benefit held up for as long as three months, and there was no clear difference between people who got one dose and those who got two. That hints a single treatment may carry patients a long way, though larger trials will need to confirm how long the relief truly lasts.
Safety and limits
Safety looked reassuring in this small group. Most side effects were mild to moderate, most often pain at the infusion site, nausea, and short-lived anxiety during the session. No serious adverse events happened. Those are encouraging signs, but 34 people is far too few to catch rare risks. The trial was also short and used careful therapeutic support, so the results may not carry over to looser real-world settings.
Practical Takeaways
- DMT is still experimental for depression and is only available through supervised clinical trials, so talk to a psychiatrist rather than seeking it on your own.
- If standard antidepressants have not worked for you, ask your doctor about clinical trials of psychedelic-assisted therapy, since eligibility depends on your history and health.
- Remember that the psychological support during dosing appears central to the benefit, so any real treatment would pair the drug with trained therapists, not the drug alone.
Related Studies and Research
- Single-dose psilocybin vs placebo: first double-blind depression trial
- A randomized controlled trial of mindfulness-based cognitive therapy for major depression
- Single-dose psilocybin shows rapid, sustained antidepressant effects
- SAMe augmentation in major depressive disorder: clinical trial
FAQs
How is DMT different from psilocybin for depression?
Both act on the same serotonin 5-HT2A receptor and both have shown antidepressant effects. The main difference is timing. DMT given through a vein clears the body in minutes, so the psychedelic experience is short and the therapy session can be brief. Psilocybin lasts several hours, which means longer sessions and more staff time. That speed is the practical edge researchers are testing with DMT.
Is DMT approved to treat depression?
No. DMT is still an experimental treatment being studied in early clinical trials. This phase IIa study is one of the first controlled tests in people with major depression, and it involved only 34 participants. Regulators need much larger trials before any approval could happen. For now, it is available only inside supervised research settings, not as a prescription.
Why did patients also get therapy along with the drug?
Psychedelic treatments in these trials are paired with psychological support before, during, and after dosing. Trained staff help patients prepare, feel safe during the experience, and make sense of it afterward. Researchers believe this support is a real part of the benefit, not just a safety measure. That is one reason experts warn against using these drugs without professional guidance.
Bottom Line
This phase IIa trial gives early but encouraging evidence that a single dose of the short-acting psychedelic DMT, paired with therapy, can produce a rapid drop in depression that lasts up to three months. The benefit was clear and the treatment was well tolerated in this small group, with no serious safety events. The short duration of DMT could make psychedelic therapy faster and more practical if larger trials confirm these results. For now, this remains a promising research treatment, not something to try outside a clinic.
